|
|
|
|
|
by sithadmin
1562 days ago
|
|
The main downside of Wegovy/semaglutide is that it is incredibly pricey ($800-$1100 USD per month), and most US health insurance providers will not cover it as a front line treatment, and many won't approve it as a second line treatment without a good deal of aggressive lobbying by the prescriber. More than one physician has told me that it's often easier to get bariatric surgery approved than it is to get Wegovy approved! This insurance issue isn't particularly unique among weight loss treatments with solid evidence-based proof of efficacy - US insurers rarely cover other typical frontline obesity treatments like phentermine + metformin, or bupropion + low dose naltrexone. These latter options are available very inexpensively as generics; semaglutide is only available in pricey branded formulations. |
|